Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a 6.8% beneficial ownership stake in Sensata Technologies Holding PLC as of June 30, 2025.

Janus Henderson Group plc has reported a 6.9% beneficial ownership stake in ARAMARK common stock, holding 17,963,599 shares.

Janus Henderson Group plc has disclosed an increased beneficial ownership of 6.9% in IDEAYA BIOSCIENCES, INC., holding 6,206,238 common shares.

Janus Henderson Group PLC has filed an Amendment No. 5 to its Schedule 13G, reporting a 7.1% beneficial ownership stake in Flex Ltd. as of June 30, 2025.

Janus Henderson Group PLC has disclosed a 7.2% beneficial ownership stake in Verona Pharma PLC, holding over 6.1 million American Depositary Shares.

Janus Henderson Group PLC has increased its beneficial ownership in Janux Therapeutics, Inc. to 7.5% of common stock, as disclosed in an amended Schedule 13G filing.

Janus Henderson Group plc has reported an 8.0% beneficial ownership stake in Structure Therapeutics Inc., holding over 4.5 million American Depositary Shares.

Janus Henderson Group plc has disclosed an 8.5% beneficial ownership stake in Akero Therapeutics, Inc. as of June 30, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Ziff Davis, Inc. to 8.5% of common stock, holding 3,568,911 shares as of June 30, 2025.

Janus Henderson Group PLC and its affiliates have reported an increased beneficial ownership of 9.4% in Teleflex Incorporated common stock.

Janus Henderson Group plc has disclosed a 9.9% beneficial ownership stake in Madrigal Pharmaceuticals, Inc., holding 2,191,753 common shares.

Janus Henderson Group plc has reported a 10.0% beneficial ownership stake in Lantheus Holdings, Inc., holding 6,938,984 common shares.

Janus Henderson Group plc and its affiliate Janus Henderson Enterprise Fund have reported beneficial ownership of 10.0% and 5.0% respectively in ICU Medical, Inc. common stock.

Janus Henderson Group plc has reported a 6.1% beneficial ownership stake in Liberty Media Corporation's Series C Liberty Formula One Common Stock.

Janus Henderson Group plc has increased its beneficial ownership in Soleno Therapeutics, Inc. to 10.5% of common stock.

Janus Henderson Group plc has disclosed an increased beneficial ownership stake of 10.6% in Mirum Pharmaceuticals, Inc. common stock as of June 30, 2025.

Janus Henderson Group plc and its affiliate have disclosed a significant beneficial ownership stake in Protara Therapeutics, Inc., totaling 10.6% of common stock.

Janus Henderson Group PLC and its affiliate report significant beneficial ownership in Mereo BioPharma Group PLC, holding 11.1% and 9.6% respectively of American Depositary Shares.

Janus Henderson Group plc and its affiliates reported an 11.3% beneficial ownership stake in WEX, Inc. common stock as of June 30, 2025.

Janus Henderson Group plc has reported an 11.4% beneficial ownership stake in Vaxcyte, Inc. common stock as of June 30, 2025.

Janus Henderson Group plc has increased its beneficial ownership in Avadel Pharmaceuticals PLC to 11.5% of common stock, holding 11,132,131 shares as of June 30, 2025.

Janus Henderson Group PLC and its affiliates have disclosed a significant passive ownership stake of 12.4% in Praxis Precision Medicines, Inc.

Janus Henderson Group plc and its affiliates have disclosed a significant beneficial ownership stake of 12.9% in Consensus Cloud Solutions, Inc. common stock.

Janus Henderson Group plc and its affiliates reported beneficial ownership of 13.3% of CIMPRESS PLC's common stock as of June 30, 2025.

Janus Henderson Group PLC and its affiliates have disclosed a significant beneficial ownership stake in 89BIO, Inc., holding 14.2% of common stock.

Janus Henderson Group plc and its affiliate reported a significant beneficial ownership stake in Bright Minds Biosciences Inc., totaling 16.3% of common stock.

Janus Henderson Group plc and its affiliates have disclosed a significant beneficial ownership stake of 19.2% in Monopar Therapeutics Inc. common stock.

Janus Henderson Group plc has increased its beneficial ownership in Ascendis Pharma A/S to 8.0% of American Depositary Shares, holding 4,427,792 shares.

Janus Henderson Group plc has reported a 4.0% beneficial ownership stake in Tenax Therapeutics, Inc., holding 166,666 shares of common stock.

Janus Henderson Group plc has reported a 0.0% beneficial ownership in Larimar Therapeutics, Inc., indicating a full divestment of its previous holdings.